MCID: UVT001
MIFTS: 57

Uveitis

Categories: Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Uveitis

MalaCards integrated aliases for Uveitis:

Name: Uveitis 12 74 58 29 54 43 15 39 17 71

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:13141
MeSH 43 D014605
NCIt 49 C26909
SNOMED-CT 67 75614007
ICD10 32 H20.9
MESH via Orphanet 44 D014605
UMLS via Orphanet 72 C0042164
Orphanet 58 ORPHA98715
UMLS 71 C0042164

Summaries for Uveitis

Disease Ontology : 12 A uveal disease is characterized by inflammation of any of the layers of the uvea of the eye, which includes the iris, ciliary body, and choroid.

MalaCards based summary : Uveitis is related to intermediate uveitis and fuchs' heterochromic uveitis. An important gene associated with Uveitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Fluocinolone Acetonide and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include eye, t cells and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Infectious Posterior Uveitis Systemic Diseases with Anterior Uveitis
Systemic Diseases with Posterior Uveitis

Diseases related to Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1107)
# Related Disease Score Top Affiliating Genes
1 intermediate uveitis 34.8 TNF IL2RA IL10 IFNG HLA-B
2 fuchs' heterochromic uveitis 34.6 TGFB2 CCL2
3 posterior uveitis 34.5 TNF SAG RBP3 IL4 IL2RA IFNG
4 blau syndrome 34.2 TNF NOD2 IL4 IL10
5 iridocyclitis 34.2 TNF RBP3 IL17A HLA-B
6 pars planitis 34.1 IL1R1 HLA-B HLA-A
7 panuveitis 33.4 TNF SAG RBP3 NOD2 IL17A IL10
8 iritis 33.4 TNF NOD2 HLA-B
9 vitreoretinopathy, neovascular inflammatory 33.3 TGFB2 CCL2 CAPN5
10 macular retinal edema 33.3 TNF ICAM1 CCL2
11 retinal vasculitis 33.2 SAG RBP3 CCL2
12 multifocal choroiditis 33.2 TNF IL10
13 choroiditis 33.0 TNF SAG RBP3 IL10 IFNG
14 sympathetic ophthalmia 33.0 TNF RBP3 IL10 ICAM1 CTLA4
15 severe cutaneous adverse reaction 33.0 TNF HLA-B HLA-A
16 spondyloarthropathy 1 32.8 TNF NOD2 IL1R1 IL17A HLA-B
17 chorioretinitis 32.8 TNF SAG RBP3 IL17A IL10 IFNG
18 vogt-koyanagi-harada disease 32.8 IL2RA IL17A IL10 IFNG HLA-B HLA-A
19 autoimmune uveitis 32.8 TRIB2 TNF SAG RBP3 IL4 IL17A
20 tropical spastic paraparesis 32.8 IL2RA IL17A IL10 IFNG HLA-B
21 autoimmune lymphoproliferative syndrome 32.6 TNF IL2RA IL10 CTLA4
22 juvenile rheumatoid arthritis 32.5 TNF IL2RA IL1R1 IL10 IFNG CTLA4
23 retinal detachment 31.9 TNF IFNG CCL2 CAPN5
24 hypopyon 31.9 RBP3 IL17A HLA-B
25 neuroretinitis 31.8 SAG IFNG
26 spondylitis 31.8 TNF NOD2 IL17A IL10 IFNG HLA-B
27 toxoplasmosis 31.8 TNF NOD2 IL4 IL10 IFNG
28 sarcoidosis 1 31.8 TNF NOD2 IL2RA IFNG ICAM1 HLA-A
29 chickenpox 31.6 TNF IL4 IL10 IFNG
30 cytomegalovirus retinitis 31.6 TNF IL10 IFNG HLA-B HLA-A
31 scleritis 31.6 TNF IL4 IFNG CCL2
32 keratopathy 31.5 TNF IL4 ICAM1
33 endophthalmitis 31.4 TNF SAG ICAM1 CRYAA
34 ocular toxoplasmosis 31.4 NOD2 IL17A
35 behcet syndrome 31.4 TNF SAG RBP3 NOD2 IL4 IL2RA
36 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.4 IL17A IL10 IFNG CTLA4
37 exanthem 31.3 TNF IL10 CTLA4
38 neuritis 31.3 TNF IL4 IL10 IFNG CCL2
39 keratitis, hereditary 31.3 TNF IL17A IL10 CRYAA
40 vasculitis 31.3 TNF IL17A IFNA2 ICAM1 HLA-B CTLA4
41 histoplasmosis 31.2 TNF IFNG HLA-B HLA-A
42 reactive arthritis 31.2 TNF IL17A IL10 IFNG HLA-B
43 neurosyphilis 31.2 IL17A IL10
44 leptospirosis 31.1 TNF IL4 IL10 IFNG CCL2
45 herpes zoster 31.1 TNF IL10 IFNG IFNA2 HLA-B HLA-A
46 retinal vascular disease 31.1 TNF ICAM1 CRYAA CCL2
47 crohn's colitis 31.1 TNF NOD2 IFNG
48 rheumatic disease 31.1 TNF IL2RA IL1R1 IL10 IFNG HLA-B
49 relapsing polychondritis 31.0 IL17A IL10 IFNG CCL2
50 rubella 31.0 TNF IL4 IL2RA IL10 IFNG HLA-B

Graphical network of the top 20 diseases related to Uveitis:



Diseases related to Uveitis

Symptoms & Phenotypes for Uveitis

GenomeRNAi Phenotypes related to Uveitis according to GeneCards Suite gene sharing:

26 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.26 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.26 HLA-A HLA-B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.26 IFNA2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.26 HLA-A HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.26 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.26 IL2RA IL1R1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.26 HLA-A HLA-B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.26 IL2RA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.26 IL1R1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.26 IL1R1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.26 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.26 IFNA2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.26 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.26 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.26 IL2RA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.26 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.26 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.26 IFNA2 IL1R1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.26 IL2RA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.26 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-174 10.26 IL2RA NOD2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.26 NOD2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.26 HLA-A HLA-B IFNA2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.26 IL1R1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.26 IL2RA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.26 HLA-A HLA-B IL2RA NOD2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.26 NOD2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.26 IL10 IL1R1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.26 IL2RA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.26 IL2RA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.26 NOD2 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.26 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.26 IL2RA IFNA2 IL10 IL1R1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.26 IFNA2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.26 HLA-A HLA-B
36 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.26 NOD2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.26 NOD2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.26 IL2RA
39 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.26 IL2RA
40 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.26 IL2RA IL10
41 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.26 IL2RA IL10
42 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.26 HLA-A HLA-B
43 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.26 HLA-A HLA-B
44 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.26 NOD2
45 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.26 IL10
46 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.26 IL10
47 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.26 IL10
48 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.26 IL2RA IL1R1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.26 IL1R1

MGI Mouse Phenotypes related to Uveitis:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.21 CAPN5 ICAM1 IFNG IL10 IL17A IL1R1
2 digestive/alimentary MP:0005381 10.18 CTLA4 ICAM1 IFNG IL10 IL17A IL2RA
3 hematopoietic system MP:0005397 10.18 CTLA4 ICAM1 IFNG IL10 IL17A IL1R1
4 homeostasis/metabolism MP:0005376 10.18 CTLA4 ICAM1 IFNG IL10 IL17A IL1R1
5 immune system MP:0005387 10.17 CAPN5 CCL2 CTLA4 ICAM1 IFNG IL10
6 endocrine/exocrine gland MP:0005379 10.16 CTLA4 ICAM1 IFNG IL10 IL17A IL1R1
7 mortality/aging MP:0010768 10.07 CAPN5 CTLA4 ICAM1 IFNG IL10 IL17A
8 craniofacial MP:0005382 10.04 IFNG IL10 IL17A IL1R1 IL4 TGFB2
9 respiratory system MP:0005388 9.81 CTLA4 IFNG IL10 IL17A IL1R1 IL2RA
10 skeleton MP:0005390 9.65 CTLA4 IFNG IL10 IL17A IL1R1 IL2RA
11 vision/eye MP:0005391 9.32 ICAM1 IFNG IL10 IL1R1 IL2RA IL4

Drugs & Therapeutics for Uveitis

Drugs for Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
4
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
5
Difluprednate Approved Phase 4 23674-86-4 443936
6
tannic acid Approved Phase 4 1401-55-4
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Fluprednisolone Approved Phase 4 53-34-9
9
Abatacept Approved Phase 4 332348-12-6 10237
10
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
11
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
12
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
13
Timolol Approved Phase 4 26839-75-8 33624 5478
14
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
15
Travoprost Approved Phase 4 157283-68-6 5282226
16
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
17
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
18
Brinzolamide Approved Phase 4 138890-62-7 68844
19
Certolizumab pegol Approved Phase 4 428863-50-7
20
Dipivefrin Approved Phase 4 52365-63-6 3105
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
23
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
24
Ranibizumab Approved Phase 4 347396-82-1 459903
25
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
26
Choline Approved, Nutraceutical Phase 4 62-49-7 305
27
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
28
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
29
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
30 Cyclosporins Phase 4
31 Calcineurin Inhibitors Phase 4
32 Anticoagulants Phase 4
33 Cathartics Phase 4
34 Laxatives Phase 4
35 Anti-Allergic Agents Phase 4
36 Antihypertensive Agents Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Lubricant Eye Drops Phase 4
39 Adrenergic Antagonists Phase 4
40 Plasma Substitutes Phase 4
41 Dextrans Phase 4
42 Adrenergic Agents Phase 4
43 Blood Substitutes Phase 4
44 Carboxymethylcellulose Sodium Phase 4
45 Olive Phase 4
46 Nootropic Agents Phase 4
47 Cytidine Diphosphate Choline Phase 4
48 Analgesics, Non-Narcotic Phase 4
49 Anti-Inflammatory Agents, Non-Steroidal Phase 4
50 Analgesics Phase 4

Interventional clinical trials:

(show top 50) (show all 415)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
4 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
5 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
6 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
7 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
8 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
9 Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis Completed NCT00589628 Phase 4 infliximab;infliximab
10 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
11 Multi-center, Randomized, Double Masked, Vehicle Controlled Phase IV Study to Compare the Efficacy, Ocular Safety and Tolerability of a Two Day Treatment With Eye Drops (0.5% Prednisolone Acetate, One Drop Four Times Per Day) in Patients With Intraocular Inflammation After Cataract Surgery, Followed by an Open Label Observational Period of 12 Days Completed NCT00170729 Phase 4 Prednisolone acetate
12 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
13 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
14 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
15 A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery Completed NCT00781300 Phase 4 Loteprednol Etabonate 0.5%;Dexamethasone 0.1%
16 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
17 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
18 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
19 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
20 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
21 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
22 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
23 Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Recruiting NCT01939691 Phase 4 Difluprednate;Nepafenac;Prednisolone acetate
24 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB Recruiting NCT04106804 Phase 4 Abatacept 125 MG/ML
25 Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves Recruiting NCT01535768 Phase 4 Aqueous Suppressant Eye Drops
26 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Active, not recruiting NCT03020992 Phase 4 Certolizumab Pegol
27 A Clinical Trial of Infliximab for Injection in Refractory Childhood Uveitis Active, not recruiting NCT04150770 Phase 4 infliximab
28 Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery Not yet recruiting NCT02917564 Phase 4 Triamcinolone Acetonide 1 ml of 40 mg/mL suspension
29 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
30 Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE Terminated NCT00918554 Phase 4 Methotrexate;Placebo
31 Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids Terminated NCT02769702 Phase 4 Acthar
32 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial Terminated NCT02684084 Phase 4 Ozurdex;Lucentis
33 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) Withdrawn NCT02598869 Phase 4 Triamcinolone Acetonide
34 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
35 Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients With Different Forms of Refractory Uveitis Acronym: Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial) Unknown status NCT00348153 Phase 2, Phase 3 Adalimumab
36 The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Unknown status NCT00012506 Phase 3 TNFR:Fc
37 Can Simvastatin Significantly Reduce the Amount of Immunosuppressive Medication Required by Patients With Sight Threatening Uveitis? A Phase 2b, Single Site, Randomized, Placebo Controlled, Double Blinded Trial. Unknown status NCT02252328 Phase 2, Phase 3 Simvastatin;Placebo
38 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
39 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
40 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
41 Study of Difluprednate in the Treatment of Uveitis Completed NCT00501579 Phase 3 Difluprednate;Prednisolone Acetate
42 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
43 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
44 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
45 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
46 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
47 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
48 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
49 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
50 A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis. Completed NCT03131154 Phase 3 ADX-102 Ophthalmic Solution (0.5%);Vehicle of ADX-102 Ophthalmic Solution

Search NIH Clinical Center for Uveitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atropine
Atropine Sulfate
Methylatropine nitrate

Cochrane evidence based reviews: uveitis

Genetic Tests for Uveitis

Genetic tests related to Uveitis:

# Genetic test Affiliating Genes
1 Uveitis 29

Anatomical Context for Uveitis

MalaCards organs/tissues related to Uveitis:

40
Eye, T Cells, Endothelial, Retina, Testes, Bone, Skin

Publications for Uveitis

Articles related to Uveitis:

(show top 50) (show all 17458)
# Title Authors PMID Year
1
Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. 54 61
20089879 2010
2
Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. 54 61
20508866 2010
3
Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressive drugs. 54 61
19551384 2010
4
Infliximab and anterior optic neuropathy: case report and review of the literature. 54 61
19916016 2010
5
Efficacy of infliximab on the acute attack of uveitis. 54 61
20062906 2010
6
Intravitreal infliximab in experimental endotoxin-induced uveitis. 54 61
19787603 2009
7
Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. 54 61
19693263 2009
8
Immune response genes in uveitis. 54 61
19657978 2009
9
Diagnosis of tuberculous uveitis: clinical application of an interferon-gamma release assay. 54 61
19576501 2009
10
Cytokine and molecular analyses of intraocular lymphoma. 54 61
19585355 2009
11
Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. 54 61
19200788 2009
12
Nucleotide oligomerization domain-2 (NOD2)-induced uveitis: dependence on IFN-gamma. 54 61
19098321 2009
13
Retinal S-antigen Th1 cell epitope mapping in patients with Behcet's disease. 54 61
18958488 2009
14
Cytokine profiles in toxoplasmic and viral uveitis. 54 61
19302012 2009
15
[Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors]. 54 61
19459572 2009
16
Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. 54 61
19234216 2009
17
Serum PEDF levels are decreased in a spontaneous animal model for human autoimmune uveitis. 54 61
19113885 2009
18
Blau syndrome-related CARD15/NOD2 mutations are not linked to idiopathic uveitis in Spanish patients. 54 61
19822951 2009
19
Developments in the scientific and clinical understanding of the spondyloarthritides. 54 61
19232062 2009
20
Evidence for endotoxin as a causative factor for leptospiral uveitis in humans. 54 61
18658094 2008
21
Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease. 54 61
19027420 2008
22
Interphotoreceptor retinoid-binding protein as biomarker in systemic autoimmunity with eye inflictions. 54 61
18266969 2008
23
Retrospective analysis of children with uveitis treated with infliximab. 54 61
18930672 2008
24
TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach. 54 61
18949668 2008
25
Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. 54 61
18580969 2008
26
[Recent advances in studies of clinical treatment of uveitis]. 54 61
19176129 2008
27
Interferon-gamma release assays in the diagnosis of tuberculous uveitis. 54 61
18804561 2008
28
Update on biologics in juvenile idiopathic arthritis. 54 61
18698187 2008
29
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. 54 61
18571896 2008
30
Spotlight on anti-CD25: daclizumab in MS. 54 61
18808743 2008
31
Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. 54 61
18579762 2008
32
Regression of vasoproliferative tumor with systemic infliximab. 54 61
18717448 2008
33
The use of infliximab in ocular inflammation. 54 61
18408083 2008
34
Mutation screening of the CARD15 gene in sarcoidosis. 54 61
18384487 2008
35
Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al. 54 61
18438832 2008
36
Link between tumor necrosis factor inhibitors and onset of uveitis: comment on the article by Lim et al. 54 61
18438831 2008
37
Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. 54 61
18438848 2008
38
NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. 54 61
18385071 2008
39
Interferon-gamma assay in tuberculous uveitis. 54 61
18369081 2008
40
Antigen-dependent monophasic or recurrent autoimmune uveitis in rats. 54 61
18203685 2008
41
[Association of ocular inflammation and innate immune response]. 54 61
18411715 2008
42
Th1 and Th2 responses on the ocular surface in uveitis identified by CCR4 and CCR5 conjunctival expression. 54 61
18222196 2008
43
TNFalpha blockade in human diseases: an overview of efficacy and safety. 54 61
17916445 2008
44
Equine recurrent uveitis--a spontaneous horse model of uveitis. 54 61
18421230 2008
45
Labrafil--a new adjuvant for peptide-specific oral tolerance in rat experimental autoimmune uveitis. 54 61
18042397 2008
46
A case report: zoledronic acid-induced anterior uveitis. 54 61
18488162 2008
47
Analysis of Crohn's disease-related CARD15 polymorphisms in Spanish patients with idiopathic uveitis. 54 61
18219096 2008
48
Aqueous humor levels of asymmetric dimethylarginine (ADMA) are positively associated with monocyte chemoattractant protein-1 (MCP-1) in patients with uveitis. 54 61
17591667 2008
49
Cytokine profile in Behçet uveitis. 54 61
19348376 2008
50
[Profile of selected cytokines in various forms of uveitis]. 54 61
19112859 2008

Variations for Uveitis

Expression for Uveitis

Search GEO for disease gene expression data for Uveitis.

Pathways for Uveitis

Pathways related to Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF NOD2 IL4 IL2RA IL1R1 IL17A
2
Show member pathways
13.86 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
3
Show member pathways
13.74 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
4
Show member pathways
13.6 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
5
Show member pathways
13.47 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
6
Show member pathways
13.36 TNF TGFB2 IL4 IL2RA IL1R1 IL17A
7
Show member pathways
13.29 TNF NOD2 IL4 IL2RA IL1R1 IL17A
8
Show member pathways
13.18 TNF TGFB2 NOD2 IL10 IFNG IFNA2
9
Show member pathways
13.04 TNF IL4 IL2RA IFNA2 HLA-B HLA-A
10
Show member pathways
13 TNF IL1R1 IFNA2 ICAM1 HLA-B HLA-A
11
Show member pathways
12.88 TNF IL2RA IFNG IFNA2 ICAM1 HLA-B
12 12.86 TNF IFNG IFNA2 HLA-B HLA-A CCL2
13
Show member pathways
12.68 TNF IL4 IL2RA IL10 IFNG
14
Show member pathways
12.68 TNF IL4 IL17A IL10 IFNG CTLA4
15
Show member pathways
12.67 TNF TGFB2 NOD2 IL4 IL2RA IL1R1
16
Show member pathways
12.65 TNF IL17A IL10 IFNG CCL2
17
Show member pathways
12.6 IFNG IFNA2 ICAM1 HLA-B HLA-A
18
Show member pathways
12.58 TNF IL4 IFNG IFNA2 ICAM1 HLA-B
19 12.57 TRIB2 TNF IL4 IL2RA IL17A IL10
20
Show member pathways
12.42 IL4 IL2RA IL10 IFNG IFNA2
21
Show member pathways
12.41 TNF IL4 IL17A IFNG CCL2
22
Show member pathways
12.41 TNF IL4 IFNG ICAM1 CCL2
23 12.38 TNF TGFB2 IL2RA IL1R1 ICAM1 HLA-B
24
Show member pathways
12.37 TNF IL2RA IL10 CCL2
25
Show member pathways
12.34 TNF TGFB2 IL4 IL10 IFNG
26 12.32 TNF TGFB2 NOD2 IL10 IFNG IFNA2
27 12.28 TNF NOD2 IFNA2 CCL2
28
Show member pathways
12.24 TNF IL4 IL1R1 IFNG
29 12.19 TNF IL1R1 IFNG ICAM1 CCL2
30 12.18 ICAM1 HLA-B HLA-A CTLA4
31
Show member pathways
12.14 TNF TGFB2 IL1R1 IL17A IL10 IFNG
32 12.11 TNF TGFB2 IL1R1 IFNG
33
Show member pathways
12.1 TNF IL4 IL2RA IL17A IL10 IFNG
34 12.09 TNF IL4 IL1R1 IFNG ICAM1 CCL2
35
Show member pathways
12.08 IL4 IL2RA IL1R1 IFNG HLA-A
36 12.07 TNF IL4 IL2RA IL10 IFNG IFNA2
37 12.05 TNF NOD2 ICAM1 CCL2
38 12.04 TNF IL4 IL17A IL10 ICAM1 CCL2
39 12.02 TNF TGFB2 IL1R1 IL10 IFNG
40 11.99 TNF TGFB2 ICAM1 CCL2
41 11.98 TNF IL4 IL2RA IL1R1
42 11.96 IL2RA IL10 IFNG IFNA2
43
Show member pathways
11.86 TNF TGFB2 IL4 IL2RA IL17A IL10
44
Show member pathways
11.85 TNF IL4 IL2RA IFNG CTLA4
45 11.84 TNF IL10 IFNG IFNA2
46 11.83 IL4 IFNG ICAM1
47 11.83 TNF TGFB2 IL17A IFNG ICAM1 CTLA4
48
Show member pathways
11.74 TNF IL2RA IFNG HLA-A
49
Show member pathways
11.71 TNF IFNG ICAM1
50 11.7 TNF IL4 CCL2

GO Terms for Uveitis

Cellular components related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 TNF TGFB2 RBP3 IL4 IL1R1 IL17A
2 extracellular space GO:0005615 9.9 TNF TGFB2 RBP3 IL4 IL17A IL10
3 cell surface GO:0009986 9.56 TNF NOD2 IL2RA IL1R1 ICAM1 HLA-B
4 MHC class I protein complex GO:0042612 9.32 HLA-B HLA-A
5 external side of plasma membrane GO:0009897 9.17 TNF IL2RA IL1R1 IL17A ICAM1 HLA-B

Biological processes related to Uveitis according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.99 TNF IL1R1 IL17A IL10 IFNA2 CCL2
2 regulation of immune response GO:0050776 9.97 IL4 ICAM1 HLA-B HLA-A
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 TNF NOD2 ICAM1 CCL2
4 cellular response to interleukin-1 GO:0071347 9.87 IL17A ICAM1 CCL2
5 regulation of inflammatory response GO:0050727 9.86 TNF NOD2 IL1R1
6 B cell differentiation GO:0030183 9.86 IL4 IL10 IFNA2
7 cellular response to organic cyclic compound GO:0071407 9.84 TNF NOD2 CCL2
8 type I interferon signaling pathway GO:0060337 9.83 IFNA2 HLA-B HLA-A
9 cellular response to lipopolysaccharide GO:0071222 9.83 TNF NOD2 IL10 ICAM1 CCL2
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL4 IFNG IFNA2
11 extrinsic apoptotic signaling pathway GO:0097191 9.79 TNF TGFB2 IFNG
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 TNF IFNG ICAM1
13 negative regulation of T cell proliferation GO:0042130 9.78 IL2RA IL10 CTLA4
14 interferon-gamma-mediated signaling pathway GO:0060333 9.78 IFNG ICAM1 HLA-B HLA-A
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.76 IL4 IL10 ICAM1
16 positive regulation of osteoclast differentiation GO:0045672 9.7 TNF IL17A IFNG
17 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IFNG
18 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
19 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.68 IL4 IL10
20 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.67 HLA-B HLA-A
21 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
22 positive regulation of NMDA glutamate receptor activity GO:1904783 9.65 IFNG CCL2
23 regulation of complement-dependent cytotoxicity GO:1903659 9.65 TGFB2 IL10
24 protection from natural killer cell mediated cytotoxicity GO:0042270 9.64 HLA-B HLA-A
25 negative regulation of cytokine secretion involved in immune response GO:0002740 9.64 TNF IL10
26 neuroinflammatory response GO:0150076 9.63 IL4 IFNG
27 type 2 immune response GO:0042092 9.63 IL4 IL10
28 regulation of regulatory T cell differentiation GO:0045589 9.63 IL2RA IFNG CTLA4
29 cell surface receptor signaling pathway GO:0007166 9.63 SAG IL2RA IL1R1 IFNG IFNA2 CCL2
30 positive regulation of interleukin-23 production GO:0032747 9.62 IL17A IFNG
31 humoral immune response GO:0006959 9.62 TNF IFNG IFNA2 CCL2
32 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL4 IL2RA IL1R1 IL17A IL10
33 positive regulation of cellular respiration GO:1901857 9.6 IL4 IFNG
34 regulation of isotype switching GO:0045191 9.59 IL4 IL10
35 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 TNF IFNG
36 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.58 NOD2 IFNG CCL2
37 receptor biosynthetic process GO:0032800 9.57 TNF IL10
38 negative regulation of alkaline phosphatase activity GO:0010693 9.56 TNF TGFB2
39 positive regulation of vitamin D biosynthetic process GO:0060557 9.55 TNF IFNG
40 positive regulation of nitrogen compound metabolic process GO:0051173 9.54 TNF IFNG
41 negative regulation of immune response GO:0050777 9.54 TGFB2 IL2RA CTLA4
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.43 IL4 IL10 IFNG
43 immune response GO:0006955 9.36 TNF IL4 IL2RA IL1R1 IL17A IL10

Molecular functions related to Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF TGFB2 IL4 IL17A IL10 IFNG

Sources for Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....